Chief Business Officer of Medace Kurt Gielen recently wrote this interesting perspective article regarding regenerative medicine together with Joshua Hunsberger and several co-authors, now published at Stem Cells Translational Medicine:
Kurt Gielen: I’d like to contribute to ensuring a smooth transition of regenerative medicine therapies to market, by supporting the professionalisation of this industry.’
‘Improving patient outcomes with regenerative medicine’:
How the Regenerative Medicine Manufacturing Society plans to move the needle forward in cell manufacturing, standards, 3D bioprinting, artificial intelligence‐enabled automation, education, and training.
